Why These 15 Stocks Are Skyrocketing in 2025

Page 5 of 14

10. AtriCure (NASDAQ:ATRC)

Number of Hedge Fund Holders In Q3 2024: 22

AtriCure (NASDAQ:ATRC) is a medical device company that sells products for atrial fibrillation (Afib), left atrial appendage management, and post-operative pain management.

The company has continued to expand its product offerings due to advancements like the cryoSPHERE MAX probe and exclusive licensing agreements for pulsed-field ablation (PFA) tech. PFA can treat Afib with fewer complications than other methods.

ATRC stock has seen a lot of bullishness due to the company expecting robust revenue growth of 17% for 2024. Revenue is expected to be $465.3 million, and 2025 revenue is expected to grow further to $517-527 million. It has also been successful in growing its international sales by 28% in Q4 2024, in addition to its strong U.S. performance. It projects an adjusted EBITDA of $40-$44 million for 2025.

Analysts have a consensus price target of $47.14 on the stock, which implies 19.34% upside potential.

The stock is up 29.9% year-to-date.

Page 5 of 14